CM326 not checked
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Keymed Biosciences Co.Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Placebo of CM326, administered subcutaneously, once every 4 weeks”In the company’s words, NCT07420257 on ClinicalTrials.gov
- Tested for
- Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- Main trialPhase 3
- “This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM326, and to observe the Pharmacokinetics, Pharmacodynamics and I immumogenicity\[c2.1\] of CM326 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).The study consists of four periods, including an up to 4-week screening/run-in period, a 24-week double-blind randomized treatment period, a 28-week open-label treatment period, and an 8-week safety follow-up period.”In the company’s words, NCT07420257 on ClinicalTrials.gov
Other drugs for Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283GSK · Phase 3
- 6113SBio · Phase 3
- DepemokimabGSK · Marketed (Phase 4 trial)
Coming up3
- 1 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Oct 2028 | A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis | |
| Phase 3Recruiting | 31 Dec 2028 | A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma | |
| Phase 2Recruiting | 1 Jul 2027 | A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | |
| Phase 1Not yet recruiting | 1 Oct 2026 | A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects | |
| Phase 2Unknown | 30 Dec 2023 | The Study of CM326 in Moderate-to-severe Atopic Dermatitis | |
| Phase 2Unknown | 28 Mar 2024 | The Study of CM326 in Adult Subjects With Atopic Dermatitis | |
| Phase 2Unknown | Jan 2025 | A Study of CM326 in Subjects With Moderate to Severe Asthma | |
| Phase 2Unknown | 30 Jun 2026 | Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis | |
| Phase 1/2Unknown | Jan 2023 | The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis | |
| Phase 1/2Completed | 29 Mar 2024 | A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps | |
| Phase 1Completed | 28 Sep 2021 | Single Ascending Dose Study of CM326 in Healthy Volunteers | |
| Phase 1Completed | 11 Oct 2022 | A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects | |
| Phase 1Completed | 4 Oct 2023 | Study of CM326 Injection in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026